JOURNAL ARTICLE

Comparative efficacy of intravenous cyclophosphamide, mycophenolate mofetil, and tacrolimus as induction therapy for lupus nephritis: A randomized controlled open-label trial.

  • Published In: Lupus, 2025, v. 34, n. 12. P. 1211 1 of 3

  • Database: Academic Search Ultimate 2 of 3

  • Authored By: Amudalapalli, Alekhya; Sahoo, Rasmi Ranjan; Shukla, Ashlesha; Maddineni, Abhichandra; Nagar, Sandeep; Sridhar, Roshani; Gadde, Sudhish; Buvanahalli Venkatshappa, Harish; Madan, Sumanth; Sasmal, Gargi; Patro, Pradeepta Sekhar 3 of 3

Abstract

This article focuses on a randomized, open-label trial comparing the efficacy and safety of intravenous cyclophosphamide (IV CYC), mycophenolate mofetil (MMF), and tacrolimus (TAC) as induction therapies for lupus nephritis (LN) in South Asian patients. The study found that TAC was non-inferior to IV CYC and MMF in achieving renal response (complete or partial) at 24 weeks, with comparable improvements in disease activity and biomarker levels, including serum CXCL10, a chemokine associated with disease activity. Adverse event profiles were similar across groups, though serious infections led to deaths in the IV CYC and TAC groups. These findings support TAC as an effective induction therapy option for LN, with further research needed to assess long-term outcomes.

Additional Information

  • Source:Lupus. 2025/10, Vol. 34, Issue 12, p1211
  • Document Type:Case Study
  • Subject Area:Health and Medicine
  • Publication Date:2025
  • ISSN:0961-2033
  • DOI:10.1177/09612033251361560
  • Accession Number:188232118
  • Copyright Statement:Copyright of Lupus is the property of Sage Publications Inc. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Looking to go deeper into this topic? Look for more articles on EBSCOhost.